MENS: MCS-2 stands out for safety and innovation, with early FDA phase III approval positioning for market entryQuartr·Sep 7 at 01:35 AMMENS+0.99%
Jyong Biotech Highlights Multi-Billion Dollar Global BPH Market Opportunity and Reaffirms Strategic Focus on Global Licensing Partnerships | MENS Stock NewsStockTitan·Jul 23 at 06:52 AMMENS+0.99%
Jyong Biotech Showcases Botanical Drug Portfolio at BIO 2026 International ConventionPR Newswire·Jul 3 at 12:00 AMMENS+0.99%
Jyong Biotech CEO Outlines FDA Pathway and Global Strategy in PharmaBoardroom Live InterviewPR Newswire·Jun 1 at 12:00 AMMENS+0.99%LABD-1.68%
Jyong Biotech Ltd. Files Annual Report on Form 20-F for Fiscal Year 2025Unusual Whales·May 15 at 12:32 PMMENS+0.99%PBE+0.13%
Jyong Biotech Updates Market Access Strategy for Innovative Botanical Drugs, Establishing Multiple Competitive Advantages for New Drug PortfolioUnusual Whales·Apr 28 at 12:31 PMMENS+0.99%LABD-1.68%
Kuo Fu-Feng Discloses Investment at Jyong Biotech with 33.34% StakeTradingView·Apr 24 at 07:16 PMMENS+0.99%
Jyong Biotech Ltd. (NASDAQ:MENS) Short Interest Down 22.7% in MarchMarket Beat·Mar 29 at 08:42 AMPBE+0.13%ARKG+0.50%
Jyong Biotech (NASDAQ:MENS) Stock Price Down 12.3% - Time to Sell?Market Beat·Feb 26 at 09:08 AMVHT-1.16%MENS+0.99%
12 Health Care Stocks Moving In Wednesday's After-Market Sessionbenzinga_article·Feb 25 at 09:07 PMVHT-1.16%BBH-0.43%
12 Health Care Stocks Moving In Monday's Intraday Sessionbenzinga_article·Feb 23 at 05:05 PMXBI+0.55%XLV-1.35%
